Src tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells

Cancer Research

Volumn 65, Issue 22, 2005, Pages 10381-10388

  George, Jessica A ^a   Chen, Ting ^a   Taylor, Christopher C ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; BETA TUBULIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN TYROSINE KINASE; RHODAMINE 123;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG RETENTION; DRUG SENSITIVITY; DRUG UPTAKE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MICROTUBULE; MITOSIS SPINDLE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICROTUBULES; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PROTEIN ISOFORMS; SRC-FAMILY KINASES; TUBULIN; UP-REGULATION;

EID: 28544449918     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1822     Document Type: Article

References (24)

1. Cannistra SA, Bast RC, Jr., Berek JS, et al. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol 2003;21 Suppl 1:129-32.
2. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995;273:491-7.
3. Cancer facts and figures. American Cancer Society; 2002. Available from: http://www.cancer.org/downloads/STT/CancerFacts&Figures2002TM.pdf.
4. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
5. Aszalos A, Ross DD. Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs. Anticancer Res 1998;18:2937-44.
6. Lu Q, Luduena RF. Removal of βIII isotype enhances Taxol induced microtubule assembly. Cell Struct Funct 1993;18:173-82.
7. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997;100:1282-93.
8. cdc2 survival checkpoint in cancer. Cancer Cell 2002;2:43-54.
9. Pengetnze Y, Steed M, Roby KR, Terranova PF, Taylor CC. Src tyrosine kinase promotes survival and resistance to chemotheraputics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun 2003;309:377-83.
10. Chen T, Pengetnze Y, Taylor CC. Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9 independent activation of caspase-3. Mol Cancer Ther 2005;4:1-8.
11. Roby KF, Taylor CC, Cheng Y, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000;21:585-91.
12. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
13. Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 2001;15:719-30.
14. Mooney DJ, Hansen LK, Langer R, Vacanti JP, Ingber DE. Extracellular matrix controls tubulin monomer levels in hepatocytes by regulating protein turnover. Mol Biol Cell 1994;5:1281-8.
15. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-73.
16. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E. The binding conformation of Taxol in β-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A 2001;98:5312-6.
17. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;277:665-7.
18. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980;77:1561-5.
19. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-25.
20. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci U S A 1993;90:9552-6.
21. Goncalves A, Braguer D, Kamath K, et al. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A 2001;98:11737-42.
22. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999;80:1020-5.
23. Kamath K, Wilson L, Cabral F, Jordan MA. βIII-Tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005;280:12902-7. Epub 2005 Feb 6.
24. Wiener JR, Windham TC, Estrella VC, et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 2003;88:73-9.